Parsons and colleagues demonstrated that overall survival in IDH1-mutant GBM was more than threefold higher than that in IDH1 wild-type GBM, and genome wide-analysis has revealed that IDH1 is mutated in approximately 12% of GBM cases.47 Excluding the patients carrying IDH mutant GBM from analysis did not change the results of the prognosis analyses (Supplementary Fig. S1 and S2). The gene discussed is IDH1; the disease is glioblastoma.